Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Biologic Science Must Evolve Before Legislative Debate – Lumpkin

Executive Summary

FDA and industry need to work out the science of generic biologics before a legislative debate would be useful, FDA Principle Associate Commissioner Murray Lumpkin, MD, suggested
Advertisement

Related Content

USP Will Release Information Chapters On Follow-On Biologics Starting In ’05
USP Will Release Information Chapters On Follow-On Biologics Starting In ’05
Biologic Monographs Could Hinder Follow-On Products – USP CEO Williams
Biologic Monographs Could Hinder Follow-On Products – USP CEO Williams
Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
§505 (BLA)?
Generic Biologics Are Coming, Commissioner McClellan Tells MBC
Bioequivalence Methods For Modified-Release Drugs To Be Examined By USP
Advertisement
UsernamePublicRestriction

Register

PS041529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel